{
    "nct_id": "NCT06508658",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group Performance status score of 0 to 2.\n* Histologically confirmed CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) and documented in the most recent and representative pathology report, inclusive of the following according to the World Health Organization (WHO) 2022 as per the protocol.\n* Must have relapsed or refractory (R/R) disease and have been previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since DLBCL diagnosis.\n* . Participant must meet at least 1 of the following criteria:\n\n  * Failed prior autologous stem cell transplant (ASCT), defined as relapsed after ASCT or been refractory to ASCT.\n  * Not be considered a candidate for ASCT due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT.\n  * Be ineligible for or unable to receive chimeric antigen receptor T-cell (CAR-T) meeting at least 1 of the following criteria:\n\n    * Unable to receive CAR-T therapy due to fitness and/or comorbidity.\n    * Lymphocyte apheresis failure.\n    * Unwilling to receive CAR-T therapy.\n    * Unable to receive CAR-T therapy due to financial, geographic, insurance, access, and/or manufacturing constraints.\n    * Relapsed/progressed after having achieved at least a Partial Response (PR) or Complete Response (CR) while on prior CAR-T therapy.\n* Must have measurable disease.\n* Life expectancy > 3 months on standard of care treatment at the time of enrolling in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current evidence of primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma including leptomeningeal disease, at screening.\n* History of prior treatment with a bispecific antibody targeting CD3 and CD20 or prior treatment with rituximab plus gemcitabine and oxaliplatin (R-GemOx) or gemcitabine and oxaliplatin (GemOx).\n* Documented refractoriness to lenalidomide.",
    "miscellaneous_criteria": ""
}